共 11 条
- [1] Disease free survival as surrogate end-point for overall survival in adjuvant taxane-based chemotherapy for breast cancer: Analysis of randomized clinical trialsANNALS OF ONCOLOGY, 2006, 17 : XI15 - XI15Ciccarese, M.Bria, E.Cuppone, F.Nistico, C.Carlini, P.Natoli, G.Nuzzo, C.Terzoli, E.Cognetti, F.Giannarelli, D.
- [2] Should disease free survival (DFS) be used as a surrogate end-point in adjuvant chemotherapy trials for non-small-cell lung cancer (NSCLC)? Analysis of 7 randomized clinical trials (RCTS) exploring platinum-based chemotherapyANNALS OF ONCOLOGY, 2007, 18 : 34 - 34Bria, EmilioCecere, Fabiana LetiziaCuppone, FedericaNistico, CeciliaMilella, MicheleFacciolo, FrancescoSperduti, IsabellaCeribelli, AnnaTerzoli, EdmondoCognetti, FrancescoGiannarelli, Diana
- [3] Cabazitaxel versus abiraterone or enzalutamide in metastatic castration-resistant prostate cancer: post hoc analysis of the CARD study excluding chemohormonal therapy for castrate-naive diseaseJAPANESE JOURNAL OF CLINICAL ONCOLOGY, 2021, 51 (08) : 1287 - 1297Suzuki, HiroyoshiCastellano, Danielde Bono, JohannSternberg, Cora N.Fizazi, KarimTombal, BertrandWulfing, ChristianFoster, Meredith C.Ozatilgan, AyseGeffriaud-Ricouard, Christinede Wit, Ronald
- [4] Should disease free survival (DFS) be used as surrogate end-point for overall survival (OS) in randomized clinical trials (RCTS) exploring adjuvant aromatase inhibitors (AIS) for breast cancer (BC)? Update of a meta-analysis looking at the magnitude of the benefitANNALS OF ONCOLOGY, 2007, 18 : 50 - 50Cuppone, FedericaBria, EmilioCiccarese, MariangelaNistico, CeciliaCarlini, PaoloSperduti, IsabellaLorusso, VitoTerzoli, EdmondoCognetti, FrancescoGiannarelli, Diana
- [5] Three-year disease-free survival (DFS) as surrogate end-point for predicting five-year overall survival (OS) benefit in adjuvant taxane-based chemotherapy for breast cancer (BC): Analysis of 10 randomized clinical trials (RCTs)JOURNAL OF CLINICAL ONCOLOGY, 2007, 25 (18)Giannarelli, D.Bria, E.Cuppone, F.Ciccarese, M.Nistico, C.Carlini, P.Milella, M.Lorusso, V.Terzoli, E.Cognetti, F.
- [6] Is 3-yrs disease-free-survival (DFS) a reliable surrogate end-point for predicting 5-yrs overall-survival (OS) benefit in adjuvant taxane-based chemotherapy for breast cancer (BC)? Analysis of randomized clinical trials (RCTS)ANNALS OF ONCOLOGY, 2007, 18 : 51 - 51Ciccarese, MariangelaBria, EmilioCuppone, FedericaCarlini, PaoloMilella, MicheleSperduti, IsabellaLo Russo, VitoNistico, CeciliaTerzoli, EdmondoCognetti, FrancescoGiannarelli, Diana
- [7] Correction: Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trialTrials, 23Nathan R. HillDaniel LassersonBen ThompsonRafael Perera-SalazarJane WolstenholmePeter BowerThomas BlakemanDavid FitzmauricePaul LittleGene FederNadeem QureshiMaarten TaalJonathan TownendCharles FerroRichard McManusF. D. Richard Hobbs
- [8] Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trialTRIALS, 2014, 15 (01)Hill, Nathan R.Lasserson, DanielThompson, BenPerera-Salazar, RafaelWolstenholme, JaneBower, PeterBlakeman, ThomasFitzmaurice, DavidLittle, PaulFeder, GeneQureshi, NadeemTaal, MaartenTownend, JonathanFerro, CharlesMcManus, RichardHobbs, F. D. Richard
- [9] Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial–a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trialTrials, 15 (1)Nathan R HillDaniel LassersonBen ThompsonRafael Perera-SalazarJane WolstenholmePeter BowerThomas BlakemanDavid FitzmauricePaul LittleGene FederNadeem QureshiMaarten TaalJonathan TownendCharles FerroRichard McManusFD Richard Hobbs
- [10] Benefits of Aldosterone Receptor Antagonism in Chronic Kidney Disease (BARACK D) trial-a multi-centre, prospective, randomised, open, blinded end-point, 36-month study of 2,616 patients within primary care with stage 3b chronic kidney disease to compare the efficacy of spironolactone 25 mg once daily in addition to routine care on mortality and cardiovascular outcomes versus routine care alone: study protocol for a randomized controlled trialTRIALS, 2014, 15Hill, Nathan R.Lasserson, DanielThompson, BenPerera-Salazar, RafaelWolstenholme, JaneBower, PeterBlakeman, ThomasFitzmaurice, DavidLittle, PaulFeder, GeneQureshi, NadeemTaal, MaartenTownend, JonathanFerro, CharlesMcManus, RichardHobbs, F. D. Richard